Despite Recent Changes in Plans, Big Pharma Maintains RNAi Partnerships | GenomeWeb

By Doug Macron

While recently announced plans
by three key big pharmas to alter their therapeutic RNAi efforts raised red flags for many industry watchers, many alliances for the gene-silencing technology remain ongoing.

Among these is a deal between Dicerna Pharmaceuticals and Japan's Kyowa Hakko Kirin, announced this week, that expands their drug-development partnership to include work in immunologic and inflammatory diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.